23 Jul, 2026
According to Straits Research, the global multiple myeloma therapeutics market size was valued at $29.49 billion in 2025 and is projected to grow from $31.28 billion in 2026 to $50.24 billion by 2034 at a CAGR of 6.1% during the forecast period 2026-2034.
Multiple myeloma is a highly uncommon kind of blood cancer that affects the white blood cells and plasma cells and develops in the bone marrow. When a patient receives treatment for multiple myeloma, the bone marrow is where the white blood cells (WBCs) begin to multiply randomly. Step-by-step procedures are used to treat multiple myeloma. The stem cell transplant is carried out once the induction therapy has been completed. In the second approach, a machine aids the patient's stem cell extraction, storage, and freezing. The cells are then reimplanted into the patient's body following this surgery. Chemotherapy containing Velcade, Cytoxan, Adriamycin, Alkeran, Thalomid, and Revlimid is another treatment option for multiple myeloma. Proteasome inhibitors are usually utilized to treat multiple myeloma in all stages of the diagnostic process, regardless of the type of therapy. The global treatment market for multiple myeloma is expanding due to the rising prevalence of numerous chronic diseases.
Increased frequency of blood malignancies, including multiple myeloma, is a crucial market driver. Despite being a rare malignancy, MM accounts for many cases globally, and there is a need for advanced therapies. Efficient and sophisticated therapies generally improve patient clinical results. It is crucial because MM is rising globally. Cancer Network reported 130,000 cases in 2016. The global multiple myeloma treatment market is expected to develop due to these factors. Due to continuous R&D, complex medicines are needed to improve prognosis.
Developing effective therapies for managing the condition, which has significantly lower cure rates, is the subject of growing R&D activity. However, several new treatments have been introduced due to significant and influential market competitors' expanding and ongoing research initiatives. For instance, the U.S. FDA declared in March 2020 that Sarclisa (isatuximab-irfc), to be administered in conjunction with two other treatments, had been approved. Although the success rates of treatments are lower, the condition is entirely treatable, which is expected to propel the growth of the global multiple myeloma market. An improved prognosis for an illness increases the likelihood that people will choose therapy, increasing the income generated by the global market.
The global multiple myeloma therapeutics market's key strength is its ability to support a wide range of products. Patients with multiple myeloma will likely have more therapy options thanks to novel medications. These cutting-edge medications won't be fighting for the same market share; instead, they'll be combined to create more efficient treatment plans, boosting each other's sales. Once more, a different combination will be used if a patient relapses. It indicates that there are significant prospects for revenue production within the projection period.
The global market for multiple myeloma therapeutics is broken down into North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa.
North America dominated the market. Rising illness prevalence, increased demand for therapy, and more advanced treatments characterize the market in the region. These characteristics, along with increased healthcare expenditures and patient population interest in innovative treatment alternatives, are responsible for the region's significant global market share. For the most part the market will be concentrated in Europe and Asia-Pacific. Regulatory approvals of essential drugs in the region and longer patent expiry dates are expected to enhance demand for European pharmaceuticals throughout the forecast period. New approvals of treatments like DARZALEX (daratumumab) in major countries like Japan and a big patient population base in the area are expected to boost market expansion in the Asia-Pacific during the forecast period. Examples of developing markets are Latin America and the Middle East and Africa. Improvements in infrastructure, including healthcare, and increasing awareness and use of sophisticated therapies will likely fuel market growth throughout the projection period.
sales@straitsresearch.com